Frazier, Vivo Add To Rempex's $67.5M In Fundraising
Rempex Pharmaceuticals Inc. raised $67.5 million in funding from investors including venture capital firms Frazier Healthcare Ventures and Vivo Ventures to continue developing treatments for bacteria resistant to antibiotics, the company...To view the full article, register now.
Already a subscriber? Click here to view full article